Podcasts about HIV

This week we're talking to two incredible humans who both share their stories of living with HIV in Out of Shadows which is about immigrants living with HIV in Ireland. Born in Himachal India, Pradesh Bhardwaj has been based in Ireland since 2021 and lived with HIV for 9 years. As an activist and proud member of the PozVibe Tribe, he is passionate about visibility, advocacy, and empowering communities. Pradeep Mahadeshwar (he/they) is a visual artist and LGBTQIA+ activist also from India but now based in Dublin. With a rich background in storytelling, writing, photography, illustrations, and filmmaking, Pradeep's work delves deeply into the complexities of identity, migration, and the lived experiences of Queer People of Colour in Ireland and beyond. He is also the founder of Queer Asian Pride Ireland and the Queer Spectrum Film Festival, Pradeep has created platforms that celebrate diversity while addressing the unique challenges faced by the immigrant LGBTQIA+ community in Ireland. Love,Veda and Robbie.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Poz Vibe Podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ is a⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Veda⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Lady and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Robbie Lawlor⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ production. Big thanks to ⁠our sponsors ⁠⁠⁠⁠⁠⁠Dublin Pride ⁠⁠⁠⁠⁠⁠who make this series possible. We'd also like to thank The Boiler House, Man 2 Man, Gay Health Network and The George for all their help and support.Episodes are produced by Veda and Robbie with production assistance and editing by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Esther O'Moore Donohoe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Artwork, social media assets and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ merch⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ all created by the fragrant Lavender The Queen.⁠⁠ ⁠⁠⁠⁠

On this week's Outcast World, Graeme Smith is asking the big question: should we finally ditch the dating apps? Author and broadcaster Daniel Harding joins the show to talk about the impact of his best-selling book Letters To My Younger Queer Self, and his new project hitting the streets to find out how queer people really feel about swiping, hookups, and love in 2025.Then, it's music time with UK Eurovision girlband Remember Monday, back with their summer anthem Happier and a Desperate Housewives-inspired music video.And stick around for a teaser of next week's exclusive with one of the breakout stars of I Kissed a Boy, opening up about HIV, mental health, and going public on national TV.NOMINATED BEST INTERVIEW PODCAST AT THE 2025 BRITISH PODCAST AWARDS - THIS IS OUTCAST WORLD---THIS IS OUTCAST WORLD ---Like and subscribe wherever you get your podcasts and please leave a review. This helps us become easier to discover. Please take time to rate the show and if you're enjoying the podcast then take time to comment about it wherever you listen. //////// Check us on Insta, Youtube and TikTok @thisisoutcastworld ///// Hosted on Acast. See acast.com/privacy for more information.

Die Europäische Kommission hat ein neues Medikament gegen HIV zugelassen. Nur zwei Spritzen pro Jahr verhindern eine Ansteckung. Sie können nun in Europa verwendet werden, der Preis steht noch nicht. Autorin: Lisa Bühren Von Daily Good News.

Kva driv ein 23-åring til å stå i lange møte, banke på dører – og sikte mot Stortinget? I denne episoden får du møte Ulvar Akselsen (Ap), lokalpolitikar på Stord og sjettekandidat i Hordaland. Vi snakkar om kvardagen i utval for rehabilitering, helse og omsorg, lærdom frå oppveksten og samtalane heime med pappa Olav Akselsen, og korleis det er å kombinera studieliv, samboarskap og valkamp.Ulvar deler tankar om velferdsstaten, skatt og små forskjellar, unge på Stortinget, kampen mot utanforskap, og korleis me kan rigga Sunnhordland for framtida – frå industri og havvind til Hordfast. Du får òg høyra korleis dørbanking faktisk kjennest, og kvifor breie kompromiss av og til er vanskelegare enn dei ser ut.Ein open og energisk prat om politikk som rører ved kvardagen vår – lokalt og nasjonalt.-----------Denne episoden har ingen sponsor.Heldigvis er det ei lita gjeng som støttar podkasten gjennom eit frivillig abonnement – noko eg set stor pris på!Om du òg set pris på Sunnhordlandpodden og vil bidra til at me kan halde fram med å heie fram gode folk i regionen vår, så er dagens utfordring til deg:Bli med på laget og teikn eit abonnement – det kostar berre 29 kroner i månaden, altså under ti kroner per episode.Hiv deg med her: ⁠⁠https://creators.spotify.com/pod/profile/sunnhordlandpodden/subscribe⁠⁠

Gregory Scarpa, known as “The Grim Reaper,” was a feared capo in the Colombo crime family and one of the most violent figures in the American Mafia. Rising to prominence in Brooklyn during the 1950s, Scarpa became infamous for his ruthless efficiency as a hitman—credited with dozens, if not hundreds, of murders. He ran rackets involving extortion, loan sharking, gambling, and narcotics, while maintaining a reputation as a stylish and brazen enforcer. His willingness to use extreme violence made him indispensable during the Colombo family's bloody internal wars, where he played a decisive role in eliminating rivals and consolidating power for his faction.Scarpa's criminal empire, however, was shadowed by his double life as a longtime FBI informant. Beginning in the early 1960s, he secretly collaborated with federal agents, reportedly even participating in the search for missing civil rights workers in Mississippi during the “Mississippi Burning” case. His relationship with the Bureau deepened in the 1980s under FBI agent Lindley DeVecchio, a partnership that sparked controversy amid claims the FBI allowed Scarpa to operate with impunity in exchange for intelligence. In 1986, he contracted HIV through a tainted blood transfusion, and by the early 1990s, he was terminally ill. Scarpa pleaded guilty to multiple murders in 1993 and died in prison in 1994 from AIDS-related complications—leaving behind a legacy as both one of the Mafia's deadliest killers and one of the FBI's most compromised informants.to contact  me:bobbycapucci@protonmail.comsource:https://www.theguardian.com/world/2007/oct/31/usa.international

In this episode of Healthline, we explore the facts about HIV, how it affects the body, and the practical steps you can take to protect yourself and stay healthy.

Salve salve. No episódio especial do Agosto Dourado, Lino recebe a infectologista Julia Mari para uma imersão no tema aleitamento humano sob a ótica da infectologia. Eles discutem desde os avanços no cenário epidemiológico do HIV no Brasil até as recomendações mais recentes para pessoas gestantes vivendo com HIV. O papo aborda dilemas éticos e clínicos, o impacto das desigualdades sociais no acesso à saúde, a importância da PrEP, além das controvérsias atuais sobre amamentação em mães com HIV — tema que envolve ciência, políticas públicas e decisões compartilhadas. Um episódio que conecta evidências, prática médica e humanização no cuidado.

Atenção senhoras e senhores ouvintes! O nosso voo acabou de decolar! E o comando desse episódio foi a integrante Beatriz Paranhos. Neste voo abordamos as notícias sobre o número de infectados de HIV, em Salvador, aumenta desde 2022, o Projeto AXÉ Oferta 140 vagas para oficinas gratuitas de aulas práticas de instrumentos e outras áreas artísticas, Ancelotti convoca o meio-campista Jean Lucas, para os jogos de eliminatória da Copa do Mundo 2026 da seleção brasileira, e o clima do Brasil pode ser influenciado pelo fenômeno "LA NINÃ", na primavera de 2025. A nossa torre de controle, no comando de Bianca Moreno, trouxe uma dica cultura muito interessante! Neste final de semana, nos dias 30 e 31 de agosto ás 19hrs, vai acontecer o espetáculo "Do outro lado do mar", no Museu de Arte da Bahia, contando com uma abordagem sobre nichos de identidade, trabalho, solidão e amizade de forma poética e reflexiva. O ingressos estão no valor de R$ 40,00 a inteira, e R$ 20,00 a meia, estando disponíveis na plataforma Sympla! Então, aperte o play e confiram notícias!

Over 1,300 athletes from 12 countries gathered at Kezar Stadium in San Francisco for the first-ever Gay Games, on 28th August, 1982.  Intended as the “Gay Olympics,” the event had to change its name at the last minute after the US Olympic Committee sued. But the opening ceremony was electric, with none other than Tina Turner performing at a pivotal moment in her career - a bold and unprecedented move for a superstar at a gay event in the early ‘80s. The brainchild of Olympic decathlete Tom Waddell, the Games were intended to show that you could be openly gay and still achieve greatness - even in a city and community plagued by HIV. Waddell prioritized inclusion over nationalism, having athletes march by city instead of country, and selected a Black gay man and cancer survivor, Richard Hunter, to light the cauldron - symbolizing unity and resilience. In this episode, Arion, Rebecca and Olly marvel at the diversity of the opening parade; reveal the child that was conceived as a direct result of the event; and consider why the Games have never been televised…  Further Reading: • ‘Tom Waddell, the amazing man behind Gay Games' (ESPN, 2014): https://www.espn.com/story/_/id/11305954/tom-waddell-amazing-man-gay-games • ‘The Gay Games are still relevant. Here's why' (The Conversation, 2018): https://theconversation.com/the-gay-games-are-still-relevant-heres-why-101104 • ‘Remembering the first Gay Games' (BBC World Service, 2022): https://www.youtube.com/watch?v=YVVD0Ww3qmo Love the show? Support us!  Join 

A Black transgender woman sued the Missouri Department of Corrections, claiming officers kept her isolated for six years based on a policy that singles out people with HIV. Missouri is now changing its policy as a result of that settlement.

Host Davide Soldato and guest Dr. John K. Lin discuss the JCO article "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-For-Service Beneficiaries with Metastatic Breast, Colorectal, Lung, and Prostate Cancer." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with authors of the latest articles published in the Journal of Clinical Oncology. I'm your host, Dr. Davide Soldato, a medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by Dr. Lin, assistant professor in the Department of Health Services Research at the University of Texas MD Anderson Cancer Center. Dr. Lin and I will be discussing the article titled, "Racial and Ethnic Disparities Along the Treatment Cascade Among  Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." Thank you for speaking with us, Dr. Lin. Dr. Lin: Thank you so much for having me. I appreciate it. Dr. Davide Soldato: So, just to start, to frame a little bit the study, I just wanted to ask you what prompted you and your team to look specifically at this question - so, racial and ethnic disparities within this specific population? And related to this question, I just wanted to ask how this work is different or builds on previous work that has been done on this research topic. Dr. Lin: Yeah, absolutely. Part of the impetus for this study was the observation that despite people who are black or Hispanic having equivalent health insurance status - they all have  Medicare Fee-for-Service - we've known that treatment and survival differences and disparities have persisted over time for patients with metastatic breast, colorectal, lung, and prostate cancer. And so, the question that we had was, "Why is this happening, and what can we do about it?" One of the reasons why eliminating racial and ethnic disparities in survival among Medicare beneficiaries with metastatic cancer has been elusive is because these disparities are occurring along a lot of dimensions. Whether or not it's because the patient presented late and has very extensive metastatic cancer; whether or not the patient has had a difficult time even seeing an oncologist; whether or not the patient has had a difficult time starting on any systemic therapy; or maybe it's because the patient has had a difficult time getting guideline-concordant systemic therapy because, more recently, these treatments have become so expensive. Disparities, we know, are occurring along all of these different facets and areas of the treatment cascade. Understanding which one of these is the most important is the key to helping us alleviate these disparities. And so, one of our goals was to evaluate disparities along the entire treatment cascade to try to identify which disparities are most important. Dr. Davide Soldato: Thank you very much. That was very clear. So, basically, one of the most important parts of the research that you have performed is really focusing on the entire treatment cascade. So, basically, starting from the moment of diagnosis up to the moment where there was the first line of treatment, if this line of treatment was given to the patient. So, I was wondering a little bit, because for this type of analysis, you used the SEER-Medicare linked database. So, can you tell us a little bit which was the period of time that you selected for the analysis? Why do you think that that was the most appropriate time to look at this specific question? And whether you feel like there is any potential limitation in using this type of database and how you handled this type of limitations? Dr. Lin: Yeah, absolutely. It's a great question. And I want to back up a little bit because I want to talk about the entire treatment cascade because I think that this is really important for our research and for future research. We weren't the first people to look at along the treatment cascade for a disease. Actually, this idea of looking along the treatment cascade was pioneered by HIV researchers and has been used for over a decade by people who study HIV. And there are a lot of parallels between HIV and cancer. One of them is that with HIV, there are so many areas along that entire treatment cascade that have to go right for somebody's treatment to go well. Patients have to be diagnosed early, they have to be given the right type of antiretrovirals, they have to be adherent to those antiretrovirals. And if you have a breakdown in any one of those areas, you're going to have disparities in care for these HIV patients. And so, HIV researchers have known this for a long time, and this has been a big cornerstone in the success of getting people with HIV the treatment that they need. And I think that this has a lot of parallels with cancer as well. And so, I am hoping that this study can serve as a model for future research to look along the entire treatment cascade for cancer because cancer is, similarly, one of these areas that requires multidisciplinary, complex medical care. And understanding where it is breaking down, I think, is crucial to us figuring out how we can reduce disparities. But for your question about the SEER-Medicare linked database, so we looked between 2016 and 2019. That was the most recent data that was available to us. And one of the reasons why we were excited to look at this is because there were some new treatments that were just released and FDA-approved around 2018, which we were able to study. And this included immunotherapy for non–small cell lung cancer, and then it also included androgen receptor pathway inhibitors, the second-generation ones, for prostate cancer. And the reason why this is important is because for some time, as we have developed these new therapies, there's been a lot of concern that there have been disparities in access to these novel therapies because of how expensive they are, particularly for the Medicare population. And so one of the reasons why we looked specifically at this time period was to understand whether or not, in more recent years, these novel therapies, people are having increasing disparities in them and whether or not increasing disparities in these more expensive, newer therapies is contributing to disparities in mortality. That being said, obviously, we're in 2025 and these data are by now six years old, and so there are additional therapies that are now available that weren't available in the past. But I think that, that being said, at least it's sort of a starting point for some of the more important therapies that have been introduced, at least for non–small cell lung cancer and prostate cancer. And the database, SEER-Medicare, is helpful because it uses the population cancer registry, which is the SEER registry cancer registry, linked to Medicare claims. So, any type of medical care that's billed through Medicare, which is going to basically be all of the medical care that these patients receive, for the most part, we're going to be able to see it. And so, I think that this is a really powerful database which has been used in a lot of research to understand what kind of care is being received that has been billed through Medicare. So, one of the limitations with this database is if there is care that's received that was not billed through Medicare, we're not going to be able to see that. And this does not happen probably that frequently, particularly because most patients who have insurance are going to be receiving care through insurance. However, we may see it for some of the oral Part D drugs. Some of those drugs are so expensive that patients cannot pay for the coinsurance during that time. And it's possible that some of those drugs patients were getting for free through the manufacturer. We potentially missed some of that. Dr. Davide Soldato: So, going a little bit into the results, I think that these are very, very interesting. And probably the most striking one is that when we look at the receipt of any type of treatment for metastatic breast, colorectal, prostate, and lung cancer - and specifically when we look at guideline-directed first-line treatments - you observed striking differences. So, I just wanted you to guide us a little bit through the results and tell us a little bit which of the numbers surprised you the most. Dr. Lin: So, what we were expecting is to see large disparities in receiving what we called guideline-directed systemic therapy. And guideline-directed systemic therapy during this time kind of depended on the cancer. So, we thought that we were going to see large disparities in guideline-directed therapy because these were the more novel therapies that were approved, and thus they were going to be the more expensive therapies. And so, what this meant was for colorectal cancer, this was going to be any 5-FU–based therapy. For lung cancer, this was going to be any checkpoint inhibitor–based therapy. For prostate cancer, this was going to be any ARPI, so this was going to be things like abiraterone or enzalutamide. And for breast cancer, this was going to be CDK4 and 6 TKIs plus any aromatase inhibitor. And so, for instance, for breast, prostate, and lung cancer, these were going to be including more expensive therapies. And so, what we expected to see was large disparities in receiving some of these more expensive, novel therapies. And we thought we were going to see fewer disparities in receiving some of the cheaper therapies, such as aromatase inhibitors, 5-FU, older platinum chemotherapies for lung cancer, and ADT for prostate cancer. We were shocked to find that we saw large racial and ethnic disparities in seeing some of the older, cheaper chemotherapies and hormonal therapies. So for instance, for breast cancer, 59% of black patients received systemic therapy, whereas 68% of white patients received systemic therapy. For colorectal, only 23% of black patients received any systemic therapy versus 34% of white patients. For lung, only 26% of black patients received any therapy, whereas 39% of white patients did. And for prostate, only 56% of black patients received any systemic therapy versus 77% of white patients. And so, we were pretty shocked by how large the disparities were in receiving these cheap, easy-to-access systemic therapies. Dr. Davide Soldato: Thank you very much. So, I just wanted to go a little bit deeper in the results because, as you said, there were striking differences even when we looked at very old and also cheap treatments that, for the majority of the patients that were included inside of your study, were actually basically available for a very small price to these patients who had the eligibility for Medicare or Medicaid. And I think that one of the very interesting parts of the research was actually the attention that you had at looking how much of these disparities could be explained by several factors. And actually, one of the most interesting results is that you observed that low-income subsidy status was actually a big determinant of these disparities in terms of treatment. So, I just wanted to guide us a little bit through these results and then just your opinion about how these results should be interpreted by policymakers. Dr. Lin: Yeah, absolutely. I'm going to explain a little bit about what low-income subsidy status is and dual-eligibility status. Some of the listeners may not know what low-income subsidy status or dual-eligibility status is. Low-income subsidy status is part of Medicare Part D. Medicare Part D is an insurance benefit that allows patients to receive oral drugs. So these are drugs that are dispensed through the pharmacy, such as the CDK4/6 inhibitors, as well as second-generation ARPIs in our study. For patients who have Medicare Part D and whose income is low enough - falls below a certain federal poverty level threshold - those patients will receive their oral drugs for much cheaper. And this is really important for some of these more novel therapies because for some of these more novel therapies, if you don't have low-income subsidy status, you may be paying thousands of dollars for a single prescription of those drugs. Whereas if you have low-income subsidy status, you may be paying less than $10. And so that difference, greater than $1,000 or $2,000 versus less than $10, one would think that the patient who's paying less than $10 would be much more likely to receive those therapies. So that's low-income subsidy status. Low-income subsidy status, importantly, doesn't apply for infused medications like immunotherapy. But it's important to know that most people with low-income subsidy status - about 88% - are also dual-eligible. What dual-eligible means is that they have both Medicare and Medicaid. Medicare being the insurance that everybody has in our study who's greater than 65. And Medicaid is the state-run but federally subsidized insurance that patients with low incomes have. And so patients who are dual-eligible - and about 87% of those with low-income subsidy status are dual-eligible - those patients have both Medicaid and Medicare, and they basically pay next to nothing for any of their medical care. And that's because Medicare will reimburse most of the medical care and the copays or coinsurance are going to be covered by Medicaid. So Medicaid is going to pick up the rest of the bill. So, most of the patients who have low-income subsidy status who are dual-eligible, these patients pay almost nothing for their medical care - Part B or Part D, any of their drugs. And so, one would expect that if cost were the main determinant of disparities in cancer care, then one would expect that dual-eligibles, most of them would be receiving treatment because they're facing minimal to no costs. What we found is that when we broke down the racial and ethnic disparity by a number of factors - including LIS status/dual eligibility, age, the number of comorbidities, etcetera - what we found was that the LIS or dual-eligibility status explained about 20% to 45% of the disparities that we saw in receiving treatment. And what that means is despite these patients paying next to nothing for their drugs, these are the most likely patients to not be treated for their cancer at all. So they're most likely to basically be diagnosed, survive for two months, see an oncologist, and then never receive any systemic therapy for their cancer. And this is not just chemotherapies for colorectal or lung cancer. This includes cheaper, easier-to-tolerate hormonal therapies that you can just take at home for breast cancer, or you can get every six months for prostate cancer, that people who even have poorer functional status are able to take. However, for whatever reason, these dual-eligible or LIS patients are very unlikely to receive treatment compared to any other patient. The low likelihood of treating this group of patients, that explains a large portion of the racial and ethnic disparities that we see. Dr. Davide Soldato: And one thing that I think is very interesting and might be of potential interest to our listeners is, did you compare survival outcomes in these different settings? And did you observe any significant differences in terms of racial and ethnic disparities once you saw that there was a significant difference when looking at both receipt of any type of treatment and also guideline-directed treatments? Dr. Lin: We saw that there were large disparities in survival by race and ethnicity when you look overall. However, when you just account for the patients who received any systemic therapy at all - not just guideline-directed systemic therapy - those differences in survival essentially disappeared. And so, what that suggests is that if black patients were just as likely to receive any systemic therapy at all as white patients, we would expect that the survival differences that we were seeing would disappear. And this is not even just looking at guideline-directed systemic therapy. This was looking just at systemic therapy alone. And so, while guideline-directed systemic therapy should be a goal, our research suggests that if we are to close the gap in disparities in overall survival among black and white patients, we must first focus on patients just receiving any type of treatment at all. And that should be the very first focus that policymakers, that leaders in ASCO, that health system leaders, that physicians, that we should focus on: just trying to get any type of treatment to our patients who are poorer or black. Dr. Davide Soldato: Thank you very much. And this was not directly related to the research that you performed, but going back to this very point - so, increasing the number of patients that receive any kind of systemic treatment before looking at guideline-directed treatments - what would you feel would be the best way to approach this in order to decrease the disparities? Would you look at interventions such as financial navigation or maybe improving referral pathways or providing maybe more culturally adapted information to the patients? Because in the end, what we see is disparities based on racial and ethnicity. We see that we can reduce these disparities if we get these patients to the treatment. But in the end, what would you feel is the best way to bring patients to these types of treatments? Dr. Lin: I think the most important thing is to understand that these disparities are not primarily happening because of the high cost of cancer treatment. These disparities are happening because of other social vulnerabilities that these patients are facing. And so these vulnerabilities could be a lot of things. It could be mistrust of the medical system. It could be fear of chemotherapy or other treatments. It could be difficulty taking time off of work. It could be any number of things. What we do know is when we've looked at the types of interventions that can help patients receive treatment, navigation is probably the most effective one. And the reason why I think that is because when patients don't receive treatment because of social vulnerability, I sort of look at social vulnerability like links in a chain. Any weakest link is going to result in the patient not receiving treatment. This may be because they have a hard time taking time off of work. This may be because they had a hard time getting transportation to their physician. It may be because they had an interaction with a physician, but that interaction was challenging for the patient. Maybe they mistrusted the physician. Maybe they're worried about the medical system. If any of these things goes wrong, the patient is not going to be treated. The patient navigator is the only person who can spot any of those weak links within the chain and address them. And so, I think that the first thing to do is to get patient navigation systems in place for our vulnerable patients throughout the United States. And this is incredibly important because in Medicare, patient navigation is reimbursable. And so this is not something that's ‘pie in the sky'. This is something that's achievable today. The second thing is that it's really important that we see these vulnerabilities happening for patients who are dual-eligible, who have both Medicare and Medicaid. One of the reasons why this is important is because there has been a lot of research outside of what we've done that has shown vulnerabilities for dual-eligible patients who have Medicare for a number of different diseases. And the reason why is because, although patients are supposed to have the benefits of both Medicare and Medicaid, usually these two insurances do not play nicely together. It creates a huge, bureaucratic, complex mess and maze that most of these patients are unable to navigate. And so many of these patients are unable to actually receive the full reimbursement from both Medicare and Medicaid that they should be getting because those two insurers are not communicating well. And so the second thing is that national cancer organizations need to be supporting policies and legislation that is already being discussed in Congress to revamp the dual-eligible system so that it facilitates these patients getting properly reimbursed for their care from both Medicare and Medicaid and these systems working together well. The third thing is that Medicaid itself has many benefits that can allow patients to receive care, like they have transportation benefits so that patients can get to and from their doctor's appointments with ease. And so I think this will be additionally very, very helpful for patients. The last thing is, you know, it's possible that future innovations such as telemedicine and tele-oncology and cancer care at home can also make it easier for some of these patients who may be working a lot to receive care. But what I would say is that our study should be a call for healthcare delivery researchers to start piloting interventions to be able to help these patients receive systemic therapy. And so what this could look like is trying to get that care navigation and implement that in clinics so that patients can be receiving the care that they need. Dr. Davide Soldato: Thank you very much. That was a very clear perspective on how we can tackle this issue. So, I just wanted to close with a sort of personal question. I was wondering what led you to work specifically in this research field that is very challenging, but I think it's particularly critical in healthcare systems like in the United States. Dr. Lin: Yeah, absolutely. One of the most important things for me as an oncologist and a researcher is being able to know that all patients in the United States - and obviously abroad - who have cancer should be able to receive the kind of care that they deserve. I don't think that patients, because their incomes are lower or because their skin looks a certain color or because they live in rural areas, these shouldn't be determinants of whether or not cancer patients are receiving the care that they need. We can develop and pioneer the very best treatments and breakthroughs in oncology, but if our patients are not receiving them - if only 20% of our patients with colon cancer or lung cancer are receiving any type of systemic therapy, who are black - this is a big problem. But this is something that I think that our system can tackle. We need to get these breakthroughs that we have in oncology to every single cancer patient in America and every single cancer patient in the world. I think this is a goal that all oncologists should have, and I think that this is something that, honestly, is achievable. I think that research is a powerful tool to give us a lens into understanding exactly why it is that certain patients are not getting the care that they deserve. And my goal is to continue to use research to shed light on why our system is not performing the way that we all want it to be. Dr. Davide Soldato: Circling back to your research, actually the manuscript that was published was supported by a Young Investigator Award by the American Society of Clinical Oncology. So, was this the first step of a more broad research, or do you have any further plans to go deeper in this topic? Dr. Lin: Yeah, absolutely. First, I want to thank the ASCO Young Investigator Award for funding this research because I think it's fair to say that this research would not have happened at all without the support of the ASCO YIA. And the fact that ASCO is doing as much as it can to support the future generation of cancer researchers is incredible. And it's a huge resource, and having it come at the time that it did is critical for so many of us. So I think that this is an unbelievable thing that ASCO does and continues to do with all of its partners. For me, yeah, this is definitely a stepping stone to further research.  Medicare Fee-for-Service is only one part of the population. I want to spread this research and extend it to patients who have other types of insurances, look at other types of policies, and also try to conduct some of the cancer care delivery research that's needed to try to pilot some interventions that can resolve this problem. So hopefully this is the first step in a broader series of studies that we can all do collectively to try to eliminate racial and ethnic disparities in cancer care and survival. Dr. Davide Soldato: So, I think that we've come at the end of this podcast. Thank you again, Dr. Lin, for joining us today. Dr. Lin: Thank you so much. It was a pleasure to be a part of this. Dr. Davide Soldato: So, we appreciate you sharing more on your JCO article, "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Although some countries are making great headway in eliminating vertical transmission of HIV, more than 100 000 infants acquire HIV each year. Maggie Walters and Michelle Bulterys talk us through their research into factors that affect the probability of vertical transmission and what it says about efforts to end new infant acquisitions.Read the full article:https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00132-8/fulltext?dgcid=buzzsprout_icw_podcast_August_25_lanhivContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Research from Dr. Adam W. Carrico at the Florida International University, and his colleagues, explores innovative approaches to address HIV prevention and treatment challenges among sexual minority men who use stimulants. Three interconnected studies examine how behavioral interventions can reduce HIV viral load, alter gene expression in immune cells, and increase the use of preventive medication in this high-priority population. Collectively, these randomized controlled trials provide compelling evidence of the potential of behavioral interventions to improve health behaviors and outcomes.

13.00 องค์การเภสัชกรรม พัฒนายาต้านไวรัส HIV ช่วยเหลือผู้ป่วยเอดส์ เข้าถึงการรักษาฟรีทุกคน ครอบคลุมทุกสิทธิการรักษา

What if one of the most misunderstood diagnoses of the past is now one of the most manageable chronic conditions? How can GPs play a pivotal role in tackling stigma, increasing testing and improving outcomes for people living with HIV?Dr James Waldron is joined by Dr Grace Bottoni (HIV and Hepatitis C GP Champion, Lewisham) for a series of podcasts about HIV. Together, they explore a range of topics with experts in the field. In this third episode, they talk with Dr Emily Mabonga (Consultant in HIV Medicine, London) about pre-exposure prophylaxis (PrEP): who it is for, how to start the conversation and practicalities around access and dosing.Access episode show notes containing key references and take-home points at:https://gpnotebook.com/en-GB/podcasts/infectious-disease/ep-171-rethinking-hiv-prevention-and-pre-exposure-prophylaxis.Did you know? With GPnotebook Pro, you can earn CPD credits by tracking the podcast episodes you listen to. Learn more.

Day 1,281.Today, we discuss reports that the US has offered air and intelligence support to a postwar force in Ukraine, the impact of strikes on Russia's energy infrastructure, and hear the latest twist in the ongoing saga of the destruction of the Nord Stream pipeline back in 2022.Contributors:Francis Dearnley (Executive Editor for Audio). @FrancisDearnley on X.Dominic Nicholls (Associate Editor of Defence). @DomNicholls on X.James Rothwell (Berlin Correspondent). @JamesERothwell on X.Content Referenced:Episode feat. interview with Commander of the Finnish Army, Lt Gen Pasi Välimäki:- Apple: https://shorturl.at/LgRLZ - Spotify: https://open.spotify.com/episode/6udyZnDmeAn6w7pY3yJ7tC - YouTube: https://www.youtube.com/watch?v=ApgMj3GpPCk Francis's Video Dispatch in Moldova:https://www.youtube.com/watch?v=gZC5FvDt-u0 Ukrainian morale suffers as troop favourite Warhammer stops translating novels (The Telegraph):https://www.telegraph.co.uk/world-news/2025/08/25/ukrainian-morale-troop-favourite-warhammer-translations-end/ US offers air and intelligence support to postwar force in Ukraine (Financial Times):https://www.ft.com/content/66ec25a0-4af8-467f-9fbe-cf42de890a7e Desperate for more soldiers, Russia recruits HIV-positive prisoners, civilians (Kyiv Independent):https://kyivindependent.com/to-fill-its-ranks-russia-seeks-hiv-positive-recruits-via-social-media-and-ukraines-occupied-territories/ US and Russian officials discussed energy deals alongside latest Ukraine peace talks (Reuters): https://www.reuters.com/business/energy/us-russian-officials-discussed-energy-deals-alongside-latest-ukraine-peace-talks-2025-08-26/ SIGN UP TO THE NEW ‘UKRAINE: THE LATEST' WEEKLY NEWSLETTER:https://secure.telegraph.co.uk/customer/secure/newsletter/ukraine/ Each week, Dom Nicholls and Francis Dearnley answer your questions, provide recommended reading, and give exclusive analysis and behind-the-scenes insights – plus maps of the frontlines and diagrams of weapons to complement our daily reporting. It's free for everyone, including non-subscribers.Subscribe: telegraph.co.uk/ukrainethelatestEmail: ukrainepod@telegraph.co.uk Hosted on Acast. See acast.com/privacy for more information.

On August 20, Missouri changed its policies around placing inmates with HIV in solitary confinement. The change stems from a lawsuit filed by Honesty Bishop: In 2015, after she was the target of an attempted sexual assault by her cellmate in a Missouri prison, prison officials deemed Bishop “sexually active” and kept her in isolation for more than 2,000 days. Bishop took her own life before the suit could conclude. Her family took it over after her death. STLPR reporter Kavahn Mansouri and Marshall Project reporter Katie Moore share their insights from reporting on the case, including their interviews with Bishop's family and analysis of Missouri's prison policies.

Martin Shkreli became a household name when he jacked up the price of a lifesaving HIV drug 5,000 percent. This quickly earned the former hedge fund manager, investor and pharmaceutical CEO the title of "The most hated man in America." But it's his shady accounting and internet trolling that lands the "Pharma Bro" in hot water. This is the story of Martin Shkreli. (Original television broadcast: 2/26/2018) Want to binge watch your Greed? Full episodes and the latest news at: https://www.cnbc.com/american-greed/

On this episode of 'The Pediatric Lounge,' hosts George and Herb are joined by Dr. Paul Offit, a renowned vaccinologist from the Children's Hospital of Philadelphia, to discuss the interplay of politics, policy, and science in vaccine administration. The conversation covers topics like the necessity of yearly boosters for older adults, the FDA and CDC approval processes, and the impact of political decisions on public health recommendations. Dr. Offit also discusses the historical and scientific context surrounding the removal of thimerosal from vaccines, the importance of aluminum as an adjuvant, and the contentious moves made by current Health and Human Services leadership. The dialogue explores recent developments in monoclonal antibody treatments for RSV, new influenza treatments, and the ongoing challenges faced by regulatory bodies in the era of COVID-19. The episode wraps up with Dr. Offit stressing the crucial need for scientifically backed decisions in public health and immunization practices.00:00 Introduction to The Pediatric Lounge00:31 Welcoming Dr. Paul Offit00:53 Discussing Vaccine Policies and Politics01:25 Family and Personal Updates01:58 The New Book Project03:01 Booster Shots for the Elderly08:15 Vaccine Advisory Committees Explained13:13 Mercury in Vaccines: A Historical Perspective23:58 Aluminum Adjuvants in Vaccines27:30 Concerns About Vaccine Injury Compensation33:37 Kennedy Family Rumors and Comparisons34:53 RFK Jr. and Vaccine Controversies35:53 Innovations in Pediatric Vaccines39:32 Challenges with Vaccine Market and Approvals41:56 HIV and Flu Vaccine Developments47:23 COVID-19 Vaccine Politics and Data Issues57:11 Maternal Vaccines and Future Directions59:35 Closing Remarks and Sign-OffSupport the show

Vymůže ministerstvo zemědělství od Agrofertu zpět více než pět miliard unijních i národních dotací? V čem je výhoda nové injekce na prevenci nákazy virem HIV, která se bude moci začít používat v Evropské unii? Zvýší EU včetně Česka tlak na Izrael kvůli postupu v Gaze a na Západním břehu? A jak těžké je vylézt na nejvyšší vrchol pohoří Ťan-šan?

In episode 55 of Going anti-Viral, Dr Darcy Wooten joins host Dr Michael Saag to discuss navigating HIV care with glucagon-like peptide-1 (GLP-1) receptor agonists. Dr Wooten is a Professor of Medicine in the Division of Infectious Diseases at Washington University in St. Louis. Her clinical interests are HIV primary care, HIV prevention, sexually transmitted infections, and general infectious diseases. Dr Wooten is also a national leader in medical education. Dr Wooten provides an overview of GLP-1 receptor agonists including their history of use for the treatment of diabetes and more recent use for treatment of weight loss. Dr Saag and Dr Wooten discuss the challenges that patients have in getting insurance coverage for GLP-1 receptor agonists and review the 2 most common drugs that are used as treatment, tirzepatide and semaglutide. They discuss the patient experience with the injectable medication and review the possibility of oral versions of the medications in the future. Finally, Dr Saag and Dr Wooten discuss the long-term management of GLP-1 receptor agonists as a part of overall primary care for patients with HIV.0:00 – Introduction1:11 – Overview of GLP-1 receptor agonists3:46 – How GLP-1 receptor agonists became used for weight management and patient eligibility criteria6:14 – Challenges of insurance coverage for GLP-1 receptor agonists8:32 – Differences between theGLP-1 receptor agonists tirzepatide and semaglutide and other benefits of the medications beyond weight loss12:04 – Patient experience with the injectable formulations and possible adverse effects of use14:36 – Long-term use of GLP-1 receptor agonists and possibility of oral versions of these drugs17:36 – Managing GLP-1 receptor agonists as a part of primary care for patients with HIV including treatment of some substance use disorders20:22 – Predictions for future management of GLP-1 receptor agonists and Dr Wooten's hope for more research into incorporating lifestyle modifications into patient care __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

This week on The Monday Edit we're talking: the Hurricane Katrina documentary, Amanda Seales & Jubilee, Texas & California redistricting, HIV segregation in prisons, and the Correct the Map campaign,. Check out the JVN Patreon for exclusive BTS content, extra interviews, and much much more - check it out here: ⁠www.patreon.com/jvn⁠  Follow us on Instagram @gettingbetterwithjvn Jonathan on Instagram @jvn and senior producer Chris @amomentlikechris  New video episodes Getting Better on YouTube every Wednesday.  Senior Producer, Chris McClure Producer, Editor & Engineer is Nathanael McClure Production support from Anne Currie, and Chad Hall Our theme music is also composed by Nathanael McClure. Curious about bringing your brand to life on the show? Email podcastadsales@sonymusic.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Kaile Eison is an Assistant Professor in the Department of Rehabilitation and Regenerative Medicine at Columbia University Irving Medical Center. She serves as the Director of Global Health and Director of HIV Rehabilitation at Columbia, as well as the Associate Director of the Inpatient Rehabilitation Unit. Her clinical and academic work centers around caring for individuals with complex medical needs, especially those recovering from intensive care or living with HIV, and developing thoughtful, comprehensive models of care. In this episode, medical student Shreya Chalapalli speaks with Dr. Eison about her unique path into PM&R, the role of rehabilitation in global health and HIV care, and how humanism guides her approach to patient care and physician well-being.

Stanley Plotkin joins TWiV to recount his career as a vaccinologist, having participated in the development of vaccines for polio, rabies, and rubella, and his thoughts on the current anti-science, anti-public health, and anti-vaccine climate. Hosts: Vincent Racaniello, Rich Condit, and Kathy Spindler Guest: Stanley A. Plotkin Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Stanley Plotkin (History of Vaccines) Talking about vaccines with Dr. Plotkin (CHOP) Path to eradication of rubella (Vaccine) Status of cytomegalovirus vaccine (J Inf Dis) Human diploid cell vaccines (Dev Biol Stand) IPV an essential part of polio eradication (Clin Inf Dis) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

Did you know hand-foot-and-mouth disease can knock an adult out for a week? Kevin Henry welcomes infectious disease and compliance expert Joyce Weeks of Dental Ed for a timely conversation on keeping dental teams safe as school is back in session and community bugs resurface. Joyce shares her journey from HIV vaccine research to teaching dental professionals about OSHA and infection control, and why understanding the “why” behind safety protocols makes all the difference. She explains how easily illnesses like hand-foot-and-mouth or measles can spread through carriers who don't even show symptoms, and why dental teams must remain vigilant long after the COVID era. From simple handwashing habits at home to choosing the right level of mask in the operatory, Joyce makes clear how small actions can protect not only dental assistants but also their families, patients, and communities. The discussion dives into the reality of what happens when a visibly sick patient shows up for treatment and how regulations differ by state. Joyce highlights the ethical and safety challenges of balancing production goals with protecting vulnerable people, and offers practical ways teams can respond without fearmongering. Through it all, she emphasizes that vigilance isn't about overreacting, but about working together to safeguard health inside and outside the office. Connect with Joyce Website: https://www.dentaledinc.com/ —-------------------------------------------- Hey friends—cool news! The Dental Assistant Nation Podcast was featured on Feedspot's Top 100 Dental Podcasts and their Top Dental Assistant Podcasts list. Huge thanks to you for listening, subscribing, and supporting the show. Couldn't have done it without you. Go check it out—we're listed alongside some amazing shows! 100 Best Dental Podcasts - https://podcast.feedspot.com/dental_podcasts/ 4 Best Dental Assistant Podcasts - https://podcast.feedspot.com/dental_assistant_podcasts/ —-------------------------------------------- Attention Dental Leaders! I'm thrilled to speak at the 2025 AADOM Conference in Round Rock, TX – AADOM's 20th anniversary celebration! Join me for my sessions: ➡️ Wednesday, Sept 3 "DPLN Leadership Meeting" - Learn how to maximize publicity for your DPLN ➡️ Saturday, Sept 6 "Simple Steps to Help You Become an Author " - We'll dive into how you can formulate a plan for your best article and how to find your voice as an industry leader. Early bird pricing ends 3/31! Don't wait—secure your spot now and be part of the biggest dental management event of the year! Plus, lock in your stay on-site at the Kalahari Resort before rooms fill up!

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/

Ícaro Silva fala da violência policial que o acompanha desde a infância e do peso de representar toda uma negritude na televisão Ícaro Silva já foi Rafa em Malhação, Wilson Simonal no teatro, Josef em Verdades Secretas e até a voz do Simba no filme Mufasa: O Rei Leão. Hoje, ele é um dos protagonistas da série Máscaras de oxigênio (não) cairão automaticamente, da HBO Max, que resgata a luta contra o HIV no Brasil dos anos 1980. No Trip FM, o ator, músico e escritor revisita uma trajetória que começou em Diadema, município do ABC Paulista, numa favela onde a enchente levou a casa da família e a violência da polícia quase levou a vida da mãe. "Me considero um sobrevivente. A arte foi o caminho que me salvou. Meus pais entenderam rápido que eu era uma criança artista, talvez até uma criança queer, e me direcionaram para esse caminho", afirmou. “Sempre entendi o racismo como uma limitação cognitiva. Quando sofria violência racista, sabia que o problema não estava comigo, mas no outro.” No papo com Paulo Lima, ele também fala sobre sexualidade, música e representatividade negra nas telas. "Ainda estamos atrasados nesse tema. Essa luta começou há 70 anos, com o Teatro Experimental do Negro. Por muito tempo me acostumei a ser o único preto em cena. Isso é uma das perversidades do racismo brasileiro: transformar uma pessoa em token para representar toda uma negritude. Nunca vi na TV uma história como a minha. Um protagonista negro e gay numa novela, por exemplo, nunca existiu." O programa fica disponível no play aqui em cima e no Spotify! [IMAGE=https://revistatrip.uol.com.br/upload/2025/08/68a8b9a0e4870/icaro-silva-ator-cantor-globo-trip-fm-mh.jpg; CREDITS=Tiago Lemos ; LEGEND=Ícaro Silva; ALT_TEXT=Ícaro Silva] Trip. Você nasceu em São Bernardo, mas cresceu em Diadema, no ABC Paulista. Como esse território marcou sua visão de mundo? Ícaro Silva. Tenho muito orgulho de ser do ABC Paulista. Quando você está na margem, você consegue enxergar muito bem o centro. Essa é a visão que a periferia me deu. Diadema nos anos 90 era uma cidade extremamente violenta, principalmente pela polícia. Eu perdi muitos amigos para a violência policial e para o tráfico. Me considero um sobrevivente. A arte foi o caminho que me salvou. Meus pais entenderam rápido que eu era uma criança artista, talvez até uma criança queer, e me direcionaram para esse caminho. O que significa para você ser queer? Na infância me chamavam de Vera Verão. Hoje eu tenho muito orgulho disso. Jorge Lafond foi um pioneiro que abriu portas e sofreu muitas violências por isso. Eu sempre fui um homem feminino e masculino ao mesmo tempo. É por isso que gosto do termo queer: ele fala de estranheza, de sair do padrão, não apenas de sexualidade. Ser queer é abraçar a própria estranheza e reconhecer que cada pessoa é única.

For years, Missouri Department of Corrections officials kept a Black transgender woman in solitary confinement. She sued the department claiming officers kept her isolated based on a policy that singles out people with HIV. The suit was settled yesterday.

Anna Person, MD, FIDSA, discusses the role of street medicine in improving access to HIV services and opportunities to support SM programs under Medicaid with Nathan Nolan, MD, MPH, MPHE, Founder of Street Medicine STL and Chris Menschner, Director, Complex Care Programs at the Center for Health Care Strategies.Shape the future of ID with peers from around the world this October at IDWeek in Atlanta, Georgia! Register today ➡️ https://registration.experientevent.com/ShowIDS251View the interactive program ➡️ https://idweek2025.eventscribe.net/

This week, Marianna sits down with John Faragon to talk about updates to guidelines surrounding pregnancy and HIV. Tune in to find out what the new recommendations are in terms of testing and treatment, who they are for, and what you need to know as an HIV care provider. -- Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

HIV, superbugs, and standards—oh my! In this episode of Absolute Gene-ius, we explore the frontier of infectious disease research with Dr. Jesús Mingorance, researcher at Hospital Universitario La Paz in Madrid. His research is translational and uses digital PCR, qPCR, sequencing, and more.Dr. Mingorance walks us through his application of ultra-sensitive PCR methods to track HIV-2 viral loads—particularly in challenging cases where standard assays fall short. He shares how digital PCR enabled detection in samples where conventional tests failed, and how it's becoming essential for assay calibration and microbial quantification. He also dives into the endemic challenges of carbapenem-resistant Klebsiella pneumoniae in hospitals, revealing the clinical and epidemiological importance of quantifying pathogen load within the microbiome.In the career corner, Dr. Mingorance recounts his unconventional journey—from humanities student to biologist inspired by a single sentence about DNA. With humor and honesty, he reflects on the patience needed in science, the value of good questions, and the importance of mentoring new scientists. “Biology is beautiful,” he reminds us. We agree.Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

In the heart of Old Town Winchester, the RISE (Resources. Inclusion. Support. Empowerment.) Community Center stands as a testament to the power of community, compassion, and resilience. Home to AIDS Response Effort (ARE), the organization has evolved over the past 35 years from a small group of volunteers supporting those affected by HIV/AIDS into a vibrant hub for HIV services, LGBTQ+ support, and community empowerment. In this conversation on The Valley Today with host Janet Michael, executive director Katie Vance shared the journey of the center's transformation, the challenges faced, and the profound impact it continues to have on the lives of local residents. The RISE Community Center's mission is multifaceted: it provides free and confidential HIV, STI, and Hepatitis C testing, case management, and a range of harm reduction services. Katie emphasized the importance of accessible testing, noting a recent uptick in positive cases since the pandemic and the center's ability to connect individuals to life-saving medications and support. “People can live long, healthy lives with the right resources,” she explained, dispelling persistent myths and highlighting the advances in HIV treatment. But the RISE Community Center is more than a healthcare provider—it's a safe haven and a gathering place. The center hosts a variety of support and affinity groups, from LGBTQ+ youth and seniors to hobby-based meetups like Stitch and Bitch. Its library, housed in a former bank vault, offers hundreds of books and resources for parents and individuals seeking understanding and affirmation. The center's gender-affirming closet, community garden, and volunteer-run programs further illustrate its commitment to holistic care. Katie and Janet discussed the ongoing need for volunteers and community advocacy, especially in the face of dwindling funding and persistent stigma. The center relies on donations and the dedication of its volunteers to keep its doors open and its programs running. Katie called on the community to not only support financially but also to challenge harmful language and myths, and to show up for LGBTQ+ neighbors. The conversation closed with a sobering reflection: without ARE and the RISE Community Center, many in Winchester would lose access to critical health services, support networks, and a sense of belonging. As Katie put it, “It's a human rights issue, not a political one.” The RISE Comunity Center's story is a powerful reminder that when a community comes together to care for its most vulnerable, everyone benefits—and hope truly rises.

This podcast was created using NotebookLM.This podcast highlights the critical link between HIV infection and oral health, emphasizing the oral cavity as an early indicator of disease progression and immune system decline.

On this episode of The Innovation Storytellers Show, I sit down with Dr. William Pao, physician scientist, former Chief Development Officer at Pfizer, and author of Breakthrough – The Quest for Life-Changing Medicines. His journey into medicine began with the loss of his father to cancer when he was just 13 years old, a moment that shaped his life's mission to develop treatments that change outcomes for patients everywhere. We explore the extraordinary, and often invisible, process of medical innovation. Dr. Pao takes us behind the scenes of eight real-world breakthroughs, revealing the persistence, failures, and unexpected turns that happen long before a drug reaches the market. He shares the story of a 15-year effort to create an HIV capsid inhibitor now given just twice a year, and how a combination of basic science curiosity and problem-solving under pressure turned a limitation into a breakthrough. We dive into the development of CRISPR-based therapies for sickle cell disease and thalassemia, a century-long scientific journey that required insights from genetics, epidemiology, and bioengineering before it could cure patients. Throughout our conversation, Dr. Pao brings these stories to life with the human elements that make them possible. We talk about the “killer experiment” mindset that helps teams decide whether to keep going or shut a project down, the value of institutional memory, and why innovation in medicine requires a rare mix of biological insight, clinical understanding, and technological advancement. We also explore the emotional side of the work, how innovators cope with fatigue, navigate internal resistance, and make hard calls when decades of work are on the line. Whether you are developing life-saving drugs or leading innovation in a completely different field, you will find practical lessons here. Dr. Pao's experiences show how to work through uncertainty, keep an open mind to ideas from outside your domain, and maintain the discipline to make good decisions even when the stakes are high.  

Prince Andrew: The Making of a Monster – an explosive deep dive into the life, scandals, and shocking secrets of the disgraced Duke of York. In this revealing investigation, biographer Andrew Lownie exposes jaw-dropping details: how women were “provided” for Andrew, his disturbing early sexual experiences, and the bizarre obsessions that shaped his adult life. From high-class prostitutes to massage parlours, from teddy bear collections to Royal Family cover-ups, this is the side of Prince Andrew the Palace doesn't want you to see. SPONSORS: Make your AI video here: https://invideo.io/i/andrewgold  Get an exclusive 15% discount on Saily data plans! Use code HERETICS at checkout. Download Saily app or go to https://saily.com/HERETICS  Go to https://ground.news/andrew  to access diverse perspectives and uncover the truth. Subscribe through my link to get 40% off unlimited access this month only. Chuck Norris: Avoid these 3 Foods Like The Plague. Watch his method by clicking the link here: https://www.ChuckDefense.com/Heretics  Cut your wireless bill to 15 bucks a month at https://mintmobile.com/heretics  Go to https://freespoke.com/gold  to search freely. Start your MyHeritage journey now with a 14-day free trial using my link: https://bit.ly/AndrewGoldMyHeritage Go to https://TryFum.com/HERETICS  and use code HERETICS to get your free FÜM Topper when you order your Journey Pack today!  Follow Andrew Lownie: https://andrewlownie.me/media  UK: Buy Entitled!: https://www.amazon.co.uk/dp/0008775451  Other countries: Link at bottom

This episode of Illuminati Radio goes into a conjoined twin giving birth to a child, we also go into Ann Marie spazzing out over rumors of her having HIV. Illuminati Radio also goes into Hassan Whiteside selling his luxury home.Hosted by your Pastor Michael Smith and co-hosted by your Brotha Lamick IsraelIf you would like tune in and join Brotha Lamick Young Disciples Discord the link is https://discord.gg/SVQygUP2 If you would like to sign up for the Monthly newsletter/ have a special request/report you would like done email Brotha Lamick Israel at Lamick19@outlook.com

Stream this podcast to learn from experts Alexis E. Horace, PharmD, BCACP,andNimish Patel, PharmD, PhD, AAHIVP, how specialist pharmacists can overcome key barriers to care and apply best practices for optimization of antiretroviral therapy for HIV. Topics covered include: Leveraging pharmacists' expertise to advance HIV treatmentPharmacist roles in HIV care and management The current ART landscapeRegimen simplificationConsideration of patient preferences, health factors, and comorbidities for ART optimizationART management for treatment-experienced patients, including those with multidrug-resistant HIVPresenters:Alexis E. Horace, PharmD, BCACPProfessor of Pharmacy PracticeUniversity of Louisiana at Monroe College of PharmacyNew Orleans CampusCrescentCare Ambulatory Care Clinical Pharmacist, HIV SpecialtyNew Orleans, LouisianaNimish Patel, PharmD, PhD, AAHIVPProfessor of Clinical PharmacyDivision of Clinical PharmacySkaggs School of Pharmacy & Pharmaceutical SciencesUniversity of California, San DiegoLa Jolla, CaliforniaLink to full program: https://bit.ly/41agtqQGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode we talk about the case of a child with HIV and PJP pneumonia.To learn more about the work of Pont Global Medicine, visit www.pontglobalmedicine.org.

In today's episode, Larry joins Angie to discuss the question, "What's the real story about AIDS?" Larry will share how Dr. Fauci fraudulently asserted that a virus (HIV) caused the AIDS epidemic. Tune in!

This is a free preview of a paid episode. To hear more, visit andrewsullivan.substack.comMy old and dear friend Johann has written four bestsellers: Chasing the Scream: The First and Last Days of the War on Drugs, Lost Connections: Uncovering the Real Causes of Depression, Stolen Focus: Why You Can't Pay Attention (discussed on the Dishcast here), and Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs (discussed here). His upcoming book is about the tunnels below Las Vegas.Four years ago we aired a 2012 interview that Johann did with me — in two parts, here and here. In this new episode we cover: my first time doing shrooms — in Amsterdam with Matt and Trey; the perversion of many Germans; my first MDMA trip in the early ‘90s; fleeing rave parties to contemplate God; a disastrous trip I experienced when Johann was present — which he calls “a dystopian version of Fawlty Towers”; ego death; Michael Pollan's How to Change Your Mind; Roland Griffiths; Johann's psychedelic theory about A Passage to India; how religious peeps integrate bad trips better than non-believers; how early HIV drugs affected a psychedelic trip; feeling agape on drugs; why psychedelics often don't affect monks and nuns very much; the 15 minutes I believed that God is evil; my mom's mental illness; the adolescent event that made me a conservative; equity in education; my teenage years in The History Boys; growing up with Keir Starmer; his wild days; our frenemy debates; the Oxford Union; my introversion; coming to America; identity politics; what Foucault got right; Virtually Normal; the Dish blog covering Obama 2008 and the Green Revolution; the indy Dish in 2013; retiring the blog after my doctor said it might kill me; the BLM summer and getting fired from New York mag; Milo Yiannopoulos; Tucker Carlson; Hitchens; The Conservative Soul; Johann prodding about my sex life; Truman; and what I want to achieve in the third trimester of my life. I apologize for TMI.Chris and I are both now enjoying a summer respite from the news and work. Hope all Dishheads are able to get some time to do the same. Perspective is so critical right now, and our culture is designed to obliterate it. See you when the new season debuts at the end of August.

The drug maker Merck recently announced its plans to start two new trials, known as the EXPrESSIVE program, testing a monthly pill for PrEP. A once-a-month PrEP pill holds great potential for the field. Even with daily pills, a monthly ring, or long acting injectables such as cabotegravir and recently FDA-approved lenacapavir, there'll be people who can't find what they really need for prevention.    For advocates who follow prevention, there's a lot to know about these trials, and powerful lessons to learn about Good Participatory Practice (GPP) and impactful involvement of stakeholders—especially community—in research. GPP has been a cornerstone of the process of design and protocol development for the EXPrESSIVE trials, and it doesn't stop there.   This episode features Merck Senior Principal Scientist Rebeca Plank and AVAC's Regional Manager for Research Engagement Grace Kumwenda. They explain why a monthly pill could be so important to HIV prevention and how GPP is shaping the design and rollout of the trials. 

Dr. Andriy Klepikov, the founder and executive director of the Alliance for Public Health (Ukraine), reflects on the Alliance's remarkable evolution over the past 25 years into a major Ukrainian—and regional—non-governmental force in HIV, TB, and harm reduction programs. Foundational to its early success was the exemplary partnership with the Global Fund and PEPFAR. Ukraine, in the midst of war, cannot at present soon transition to self-reliance. In the past three and a half years of war following the Russian invasion, the Alliance has become a provider of mass emergency humanitarian relief to the most vulnerable in Ukraine. It now serves five times the numbers it served before the war. Recovery will draw on telemedicine and mobile clinics, and prioritize mental health, war veterans who are blinded, have lost limbs, and struggle with long-term trauma. The United States remains indispensable to Ukraine's future—for peace and social justice.  

About this episode: The Department of Health and Human Services has cancelled nearly $500 million in funding for the development of mRNA vaccines, including for vaccines against potential new pandemic threats. In this episode: Professor Bill Moss delves into the misinformation surrounding mRNA vaccines, explains their potential to treat diseases like cancer and HIV, and warns of the national security threats posed by cuts to development. Guest: Dr. Bill Moss, MPH, is an infectious disease specialist and the executive director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs. Show links and related content: Johns Hopkins expert speaks on ripple effect of federal cuts to mRNA vaccine contracts—WBAL-TV 11 How Cuts to mRNA Vaccine Development Will Set the U.S. Back—Johns Hopkins Bloomberg School of Public Health What to know about mRNA vaccines as Trump admin pulls funding—Axios For mRNA Vaccines, COVID-19 Is Just the Beginning—Johns Hopkins Bloomberg School of Public Health Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Tom Frieden is the president and chief executive officer of Resolve to Save Lives and former director of the Centers for Disease Control and Prevention. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. T.R. Frieden. Dismantling Public Health Infrastructure, Endangering American Lives. N Engl J Med 2025;393:625-627.

Another feed swap this week - with The Queer Family Podcast with Jaimie Kelton! . . . Jaimie sits down with Brian Rosenberg, longtime advocate, dad of three, and founder of Gays With Kids and GWK Academy. From navigating HIV and homophobia in the '80s to building a beautiful family through adoption and surrogacy, Brian shares his powerful story with honesty, humor, and heart. He opens up about the challenges of coming out as HIV-positive before coming out as gay, what it was like to raise kids during a time when queer family building had very little visibility, and why he's now dedicated to making the process easier for all LGBTQIA+ folks looking to become parents. You'll laugh, cry, and walk away feeling a little more seen.  “I'm one of the first out gay men living with HIV to have biological kids through surrogacy. Now there are hundreds of us—and counting.” – Brian Rosenberg Learn more about your ad choices. Visit megaphone.fm/adchoices

About this episode: As the United States grows more polarized along regional, political, and ideological lines, it is critical to resolve conflict civilly—particularly when it comes to pressing public health concerns that implicate all of us. In this episode: Peace building experts David Addiss and John Paul Lederach draw on their careers in conflict resolution and public health to share strategies for building relationships, restoring trustworthiness, and fostering solutions-oriented conversations to bridge ideological gaps. Guest: Dr. David Addiss, MPH, is a public health doctor whose career has involved migrant health, mountain medicine, neglected tropical diseases, research, philanthropy, and global health. He is the Director of the Focus Area for Compassion and Ethics at the Task Force for Global Health. John Paul Lederach, PhD, is Professor Emeritus at the University of Notre Dame and a Senior Fellow with Humanity United. He is widely known for the development of culturally-based approaches to conflict transformation and the design and implementation of integrative and strategic approaches to peace building. Host: Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health. Show links and related content: A Recipe for Cooling Down American Politics—Washington Post Facing Down a Civil War—www.johnpaullederach.com Here To Understand: How Braver Angels Is Orchestrating Tough Public Health Conversations—Public Health On Call (June 2025) Peacebuilding to Help Mend A Broken World—Public Health On Call (December 2023) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

In the world of fashion, there are a handful of names that do more than just design clothes—they shape conversations. Our guest today is someone who's done exactly that. Founder, chairman and creative director of the immensely popular fashion brand that shares his name: Kenneth Cole. Not only is Kenneth a wildly successful fashion designer and entrepreneur—he's also a bold voice for social change, and an influential supporter and advocate for HIV research, mental health awareness and several other human rights initiatives. Since launching his brand Kenneth Cole Productions in the early '80s out of a trailer on the streets of New York to becoming globally recognized for blending great style with meaningful purpose, Kenneth has been intentionally crafting a business that feels deeply personal. Kenneth talks about the steps he took to bring attention and credibility to his fledgling startup shoe company, what it's meant to him to be able to use his platform for good and why creating impactful messaging that lingers can be the absolute best thing for your brand. Thanks for tuning in to episode 93. We hope you enjoy it! Did you know that YOU can be on The Nordy Pod? This show isn't just a one-way conversation. We want to hear about what Nordstrom looks like through your eyes. Share your Nordstrom experience, good or bad, by giving us a call and leaving a voicemail at 206.594.0526, or send an email to nordypodcast@nordstrom.com to be a part of the conversation! And be sure to follow us on Instagram @thenordypod to stay up to date on new episodes, announcements and more.

This week on Face the Nation, President Trump invites Russia's Vladimir Putin to America, his first visit to U.S. soil in a decade. After months of Russia skirting cease-fire offers while continuing their brutal onslaught in Ukraine, President Trump skipped past his own sanctions deadline and instead invited Putin to Alaska. We hear from Ukrainian Ambassador Oksana Markarova about what her country needs to agree to a cease-fire. Plus, we ask NATO Secretary General Mark Rutte what a potential deal might mean for European security. Then, Arizona Democratic Senator Mark Kelly and Texas Republican Congressman Tony Gonzales, two lawmakers from border states, tell us how the fresh infusion of cash from Trump's massive domestic policy bill is affecting mass deportation efforts in their states. Finally, the Trump administration says it will slash funding for mRNA vaccine research, an emerging field used in COVID vaccines that also showed promise in treating cancer and HIV. We'll get analysis from Doctor Jerome Adams, who was Surgeon General in Trump's first term. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

TWiV discusses the latest worrisome Executive Order on oversight of federal grantmaking, RFK Jr winds down mRNA viral vaccine development, Lenacapavir, a drug for AIDS prevention and treatment, and how respiratory virus infections awaken dormant metastatic breast cancer cells in lungs. Hosts: Vincent Racaniello, Alan Dove, Rich Condit and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Oversight of Federal grantmaking (Whitehouse.gov) Grantmaking gets a Christofascist (Rasmussen Retorts) HHS winds down mRNA vaccine development (HHS) Lives saved by COVID vaccines (JAMA) Lenacapavir review (Bicochem Pharm) UNAIDS urges Gilead to lower price of lenacapavir (UNAIDS) Gilead and price gouging (Wikipedia) Respiratory virus infections awaken metastatic breast cancer (Nature) Letters read on TWiV 1243 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – Xkcd: Geologic Periods Rich – Old Man's War by John Scalzi Alan – The Broken Earth trilogy by N. K. Jemisin Vincent – Cacio e pepe: Good Food pasta recipe sparks fury in Italy Listener Pick Linda – DNA captured in air could identify life forms Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.